Bosh sahifaHELP • NASDAQ
add
Cybin Inc
Yopilish kursi
7,61 $
Kunlik diapazon
7,22 $ - 8,10 $
Yillik diapazon
5,76 $ - 8,97 $
Oʻrtacha hajm
520,82 ming
Narx/foyda
-
Dividend daromadliligi
-
Bozor yangiliklari
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (CAD) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Daromad | — | — |
Joriy xarajat | 33,24 mln | 31,95% |
Sof foyda | -30,58 mln | -43,25% |
Sof foyda marjasi | — | — |
Har bir ulushga tushum | -1,46 | -92,11% |
EBITDA | -33,19 mln | -32,03% |
Amaldagi soliq stavkasi | — | — |
Balans
Jami aktivlari
Jami passivlari
| (CAD) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 135,02 mln | -35,39% |
Jami aktivlari | 258,62 mln | -14,37% |
Jami passivlari | 21,42 mln | 112,14% |
Umumiy kapital | 237,20 mln | — |
Tarqatilgan aksiyalar | 23,03 mln | — |
Narxi/balansdagi bahosi | 0,69 | — |
Aktivlardan daromad | -32,45% | — |
Kapitaldan daromad | -34,81% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (CAD) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -30,58 mln | -43,25% |
Operatsiyalardan naqd pul | -21,11 mln | -1,96% |
Sarmoyadan naqd pul | -1,08 mln | -404,19% |
Moliyadan naqd pul | 20,98 mln | -89,01% |
Naqd pulning sof oʻzgarishi | -1,27 mln | -100,75% |
Boʻsh pul | -11,14 mln | 12,30% |
Haqida
Helus Pharma, also known formerly as Cybin IRL, is a Canadian pharmaceutical company that is developing psychedelic drugs as medicines.
The company's drug candidates include psilocybin, HLP002, HLP003, HLP004, HLP005, and HLP006. Another drug that the company has developed is CYB210010.
As of January 2025, HLP003 is in phase 3 clinical trials. The drug is one of the only other psychedelics besides Compass Pathways's COMP360 to have reached this late stage of clinical development.
In 2020, Helus Pharma acquired psychedelic pharmaceutical company Adelia Therapeutics. Helus Pharma was originally known as Cybin but changed its name in December 2025. Wikipedia
Tashkil etilgan
2019
Bosh ofis
Sayt
Xodimlar soni
50
